Short and Long-Term Effects of Prebiotic, Probiotic and Synbiotic on Appetite and Dietary Intake

Prebiotics and probiotics are thought to play a role in appetite control and body weight regulation; but little is known about this topic. This study was planned to examine the effects of inulin and Lactobacillus casei 431 on short and long term fasting, satiety, dietary intake, and serum hunger and satiety hormone levels. The study consisted of 2 phases. In the first phase, a double-blind, randomized, crossover study design was used, and it was performed with 16 healthy male participants aged 19-30 years. In this phase, the prebiotic (200mL milk+16g inulin), probiotic (200mL milk + Lactobacillus casei 431 [>106 cfu/mL]+16g maltodextrin), synbiotic (200mL milk+16g inulin + Lactobacillus casei 431 [>106 cfu/mL]) and control (200mL milk+16g maltodextrin) test drinks were consumed with a standard breakfast on four separate test days by one week intervals, and their effects on dietary intake, hunger, satiety and appetite were assessed. The second phase was performed with 21 healthy male participants aged 19-30 years, using a placebo-controlled double-blind, randomized study design. Participants consumed the control (200mL milk+16g maltodextrin) or synbiotic (200mL milk+16g inulin+ Lactobacillus casei [>106 cfu/mL]) test drinks for 21 days with their habitual diet. At the beginning and end of the intervention, blood samples were collected at 0., 30., 60. and 120. minutes following the test day protocol to analyse serum glucose, insulin, ghrelin, obestatin and PYY (peptide tyrosine tyrosine) levels. In addition, dietary intake, hunger, satiety and appetite of participants were compared.

Study Overview

• Status: Completed
• Conditions: Body Weight; Appetite; Dietary Intake
• Intervention / Treatment: Other: Control drink; Other: Synbiotic test drink

• Study Type: Interventional
• Enrollment (Actual): 21
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Ankara, Turkey, 06230
    • Hacettepe University, Faculty of Health Sciences, Department of Nutrition and Dietetics

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 30 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Healthy male
• 19-30 years old
• Body mass index (BMI) of 18.5-29.9 kg/m2

Exclusion Criteria:

• Being female
• Being younger than 19 years old or older than 30 years old
• Having a BMI that is lower than 18.5 kg/m2 or higher than 29.9 kg/m2
• Smoking
• Having any metabolic disease
• Losing or gaining weight in the past 3 months
• Following a special diet
• Using any medicine which could affect the outcome of the study
• Having food intolerance and allergies
• Taking regular probiotic or prebiotic foods or supplements
• Not consuming breakfast or lunch regularly
• Being a professional athlete
• Having unhealthy eating attitude that assessed using three factor eating questionnaire (having cognitive restraint score >13, uncontrolled eating score >18, and emotional eating > 6)
• Having depression that was assessed using Beck's Depression Inventory (having a score >9)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Control drink; 200 mL milk + 16 g maltodextrin	Other: Control drink; In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g maltodextrin per day for 21 days with their habitual diet.
Active Comparator: Test drink; 200 mL milk + 16 g inulin + Lactobacillus casei [>106 cfu/mL]	Other: Synbiotic test drink; In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g inulin + Lactobacillus casei431 [>106cfu/mL] per day for 21 days with their habitual diet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in dietary energy and nutrient intakes by 3-day dietary record method	Energy and nutrients intakes were assessed using a 3-day dietary record method at baseline (including the mean dietary intake of Day -3, Day -2 and Day -1) and at end of the intervention (including the mean dietary intake of Day 19, Day 20 and Day 21).	At the beginning and end of the intervention (Day 0 and Day 21)
Change in appetite sensations	Appetite sensation was measured using 100-mm visual analog scale with a minimum value of 0 and a maximum value of 100 at six points including before the breakfast (0.) and following 30., 60., 90., 120. and 180. minutes. Lower scores mean a better outcome.	0., 30., 60., 90., 120. and 180. minutes at the beginning and end of the intervention (Day 0 and Day 21)
Change in body weight	Body weight was measured	At the beginning and end of the intervention (Day 0 and Day 21)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in area under the serum glucose concentration versus time curve (AUC)	Serum glucose concentrations were measured at four point including before the breakfast (0.) and following 30., 60. and 120. minutes to provide a curve.	0., 30., 60. and 120. minutes at the beginning and end of the intervention (Day 0 and Day 21)
Change in area under the serum insulin concentration versus time curve (AUC)	Serum insulin concentrations were measured at four point including before the breakfast (0.) and following 30., 60. and 120. minutes to provide a curve.	0., 30., 60. and 120. minutes at the beginning and end of the intervention (Day 0 and Day 21)
Change in area under the serum obestatin concentration versus time curve (AUC)	Serum obestatin concentrations were measured at four point including before the breakfast (0.) and following 30., 60. and 120. minutes to provide a curve.	0., 30., 60. and 120. minutes at the beginning and end of the intervention (Day 0 and Day 21)
Change in area under the serum ghrelin concentration versus time curve (AUC)	Serum ghrelin concentrations were measured at four point including before the breakfast (0.) and following 30., 60. and 120. minutes to provide a curve.	0., 30., 60. and 120. minutes at the beginning and end of the intervention (Day 0 and Day 21)
Change in area under the serum PYY concentration versus time curve (AUC)	Serum PYY concentrations were measured at four point including before the breakfast (0.) and following 30., 60. and 120. minutes to provide a curve.	0., 30., 60. and 120. minutes at the beginning and end of the intervention (Day 0 and Day 21)
Change in serum fasting adiponectin concentration	Serum fasting adiponectin concentrations were measured at the beginning and end of the intervention	At the beginning and end of the intervention (Day 0 and Day 21)
Change in dietary energy and nutrient intakes by diet diary method	Energy and nutrients intakes were also assessed using diet diary method during 21-day intervention to confirm the changes assessed by 3-day dietary record.	Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 11, Day 12, Day 13, Day 14, Day 15, Day 16, Day 17, Day 18, Day 19, Day 20, Day 21

Collaborators and Investigators

• Sponsor: Hacettepe University
• Collaborators: Ankara University
• Investigators: Principal Investigator: Zehra Buyuktuncer, PhD, Prof, Hacettepe University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2016
• Primary Completion (Actual): July 5, 2018
• Study Completion (Actual): July 5, 2018

Study Registration Dates

• First Submitted: December 19, 2019
• First Submitted That Met QC Criteria: December 25, 2019
• First Posted (Actual): December 27, 2019

Study Record Updates

• Last Update Posted (Actual): December 27, 2019
• Last Update Submitted That Met QC Criteria: December 25, 2019
• Last Verified: December 1, 2019

More Information

Terms related to this study

• Keywords: prebiotic; probiotic; synbiotic; hunger and satiety hormones
• Additional Relevant MeSH Terms: Body Weight
• Other Study ID Numbers: THD-2017-15479

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No